



ASERVO® EQUIHALER®

Designed  
specifically for  
horses

Designed for horses, the Aservo® EquiHaler® makes breathing easier.



>95%

Well accepted by  
most horses <sup>21, 22</sup>

>93%

High owner  
compliance <sup>21, 22</sup>

## EASY TO USE

## MADE FOR HORSES



Nostril adapter



BreathView® breath indicator



Single use



Single-hand maneuver



Simple treatment protocol



Fill indicator

Snug fit in the equine nostril  
serves as reservoir for the drug

Easy timing with beginning of inhalation

Minimizes risk for cross-contamination  
between horses

Second hand is free to aid in handling  
the horse

One dose fits all

Easy monitoring of drug solution level

Optimize control of inflammation while  
minimizing the risk for side effects



## Aservo® EquiHaler®

---

Soft Mist™ is  
easily inhaled into  
the lower airway<sup>17</sup>

---

Local drug activity  
deep within the lung<sup>18</sup>

---

Favorable safety  
profile<sup>19, 20</sup>



---

Highly potent prodrug  
reduces inflammation  
to decrease airway  
obstruction<sup>18</sup>

---

Accepted by >95%  
of horses<sup>21, 22</sup>

---

Studied in over 600 horses  
under controlled and field  
conditions<sup>19, 21, 22, 23</sup>

1. Couëtil, L.L., Cardwell, J.M., Gerber, V., Lavoie, J.P., Léguillette, R. and Richard, E.A., 2016. Inflammatory airway disease of horses—revised consensus statement. *Journal of veterinary internal medicine*, 30(2), pp.503-515.
2. Mazan, M.R., 2015. Update on noninfectious inflammatory diseases of the lower airway. *Veterinary Clinics: Equine Practice*, 31(1), pp.159-185.
3. Burrell, M.H., Wood, J.L.N., Whitwell, K.E., Chanter, N., Mackintosh, M.E. and Mumford, J.A., 1996. Respiratory disease in thoroughbred horses in training: the relationships between disease and viruses, bacteria and environment. *Veterinary Record*, 139(13), pp.308-313.
4. Wasko, A.J., Barkema, H.W., Nicol, J., Fernandez, N., Logie, N. and Léguillette, R., 2011. Evaluation of a risk screening questionnaire to detect equine lung inflammation: results of a large field study. *Equine veterinary journal*, 43(2), pp.145-152.
5. Couëtil, L.L., Ward MP., 2003. Analysis of risk factors for recurrent airway obstruction in North American horses: 1,444 cases (1990-1999). *J Am Vet Med Assoc*. 223:1645–50.
6. Hotchkiss, J.W., Reid, S.W.J. and Christley, R.M., 2007. A survey of horse owners in Great Britain regarding horses in their care. Part 2: Risk factors for recurrent airway obstruction. *Equine veterinary journal*, 39(4), pp.301-308
7. Swiderski, C.E., Bowser, J.E. and Costa, L.R.R., 2017. Pasture associated asthma. *Proceedings of the American College of Veterinary Internal Medicine*, National Harbor, Maryland, USA.
8. Art, T., McGorum, B.C. and Lekeux, P., 2002. Environmental control of respiratory disease. *Equine respiratory diseases*.
9. Clements, J.M. and Pirie, R.S., 2007. Respirable dust concentrations in equine stables. Part 1: validation of equipment and effect of various management systems. *Research in veterinary science*, 83(2), pp.256-262.
10. Gerber, V., Baleri, D., Klukowska Rötzler, J., Swinburne, J.E. and Dolf, G., 2009. Mixed inheritance of equine recurrent airway obstruction. *Journal of veterinary internal medicine*, 23(3), pp.626-630.
11. Houtsma, A., Bedenice, D., Pusterla, N., Pugliese, B., Mapes, S., Hoffman, A.M., Paxson, J., Rozanski, E., Mukherjee, J., Wigley, M. and Mazan, M.R., 2015. Association between inflammatory airway disease of horses and exposure to respiratory viruses: a case control study. *Multidisciplinary respiratory medicine*, 10(1), p.33.
12. Hoffman, A.M., 2002. Clinical application of pulmonary function testing in horses. *Equine respiratory diseases international veterinary information service Ithaca*, DocumentNo B, 3040802.
13. Bullone M, Lavoie J-P. Science-in-brief: Equine asthma diagnosis: beyond bronchoalveolar lavage cytology. *Equine Vet*

14. Gerber, V., Schott li, H.C. and Robinson, N.E., 2011. Owner assessment in judging the efficacy of airway disease treatment. *Equine veterinary journal*, 43(2), pp.153-158.
15. Pirie, R.S., 2018. Severe equine asthma—an overview. *Equine Health*, 2018(39), pp.21-28.
16. Mazan, M.R., 2017. Therapy and Management of Equine Asthma. *Proceedings of the American Association of Equine Practitioners*, San Antonio, Texas, USA.
17. Dalby, R., Spallek, M. and Voshaar, T., 2004. A review of the development of Respimat® Soft Mist™ Inhaler. *International journal of pharmaceuticals*, 283(1-2), pp.1-9.
18. Mukker, J.K., Singh, R.S.P. and Derendorf, H., 2016. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. *Journal of pharmaceutical sciences*, 105(9), pp.2509-2514.
19. Lavoie, J.P., Bullone, M., Rodrigues, N., Germim, P., Albrecht, B. and von Salis Soglio, M., 2019. Effect of different doses of inhaled ciclesonide on lung function, clinical signs related to airflow limitation and serum cortisol levels in horses with experimentally induced mild to severe airway obstruction. *Equine veterinary journal*.
20. Derom, E., Van De Velde, V., Marissens, S., Engelstätter, R., Vincken, W. and Pauwels, R., 2005. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5' monophosphate in asthmatic patients. *Pulmonary pharmacology & therapeutics*, 18(5), pp.328-336.
21. Data on file 1: Pivotal EU study
22. Data on file 2: Pivotal US study
23. Data on file 3: Target Animal Safety